Aridis Pharmaceuticals Inc
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin… Read more
Market Cap & Net Worth: Aridis Pharmaceuticals Inc (ARDS)
Aridis Pharmaceuticals Inc (PINK:ARDS) has a market capitalization of $0.91 ($0.91) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #46373 globally and #14465 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aridis Pharmaceuticals Inc's stock price $0.00 by its total outstanding shares 9118 (9.12K).
Aridis Pharmaceuticals Inc Market Cap History: 2018 to 2025
Aridis Pharmaceuticals Inc's market capitalization history from 2018 to 2025. Data shows change from $101.12K to $0.91 (-83.01% CAGR).
Aridis Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aridis Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Aridis Pharmaceuticals Inc's market cap is 0.00 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $101.12K | $2.76 Million | -$22.11 Million | 0.04x | N/A |
| 2019 | $40.58K | $1.02 Million | -$28.99 Million | 0.04x | N/A |
| 2020 | $55.35K | $1.00 Million | -$22.33 Million | 0.06x | N/A |
| 2021 | $21.24K | $1.53 Million | -$42.28 Million | 0.01x | N/A |
| 2022 | $10.76K | $19.25 Million | -$30.75 Million | 0.00x | N/A |
Competitor Companies of ARDS by Market Capitalization
Companies near Aridis Pharmaceuticals Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Aridis Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Aridis Pharmaceuticals Inc Historical Marketcap From 2018 to 2025
Between 2018 and today, Aridis Pharmaceuticals Inc's market cap moved from $101.12K to $ 0.91, with a yearly change of -83.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $0.91 | 0.00% |
| 2024 | $0.91 | -99.86% |
| 2023 | $639.17 | -94.06% |
| 2022 | $10.76K | -49.36% |
| 2021 | $21.24K | -61.61% |
| 2020 | $55.35K | +36.40% |
| 2019 | $40.58K | -59.87% |
| 2018 | $101.12K | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Aridis Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $0.91 USD |
| MoneyControl | $0.91 USD |
| MarketWatch | $0.91 USD |
| marketcap.company | $0.91 USD |
| Reuters | $0.91 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.